The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Edwards Lifesciences missed estimates on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share contracted.
Gross margins improved, operating margins contracted, and net margins dropped.
Edwards Lifesciences recorded revenue of $430.2 million. The 22 analysts polled by S&P Capital IQ foresaw net sales of $447.4 million. Sales were 9.6% higher than the prior-year quarter's $392.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.62. The 26 earnings estimates compiled by S&P Capital IQ averaged $0.59 per share on the same basis. GAAP EPS of $0.53 for Q4 were 1.9% lower than the prior-year quarter's $0.54 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 72.2%, 110 basis points better than the prior-year quarter. Operating margin was 20.1%, 40 basis points worse than the prior-year quarter. Net margin was 14.7%, 180 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $464.7 million. On the bottom line, the average EPS estimate is $0.55.
Next year's average estimate for revenue is $2.01 billion. The average EPS estimate is $2.77.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 149 members out of 203 rating the stock outperform, and 54 members rating it underperform. Among 71 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Edwards Lifesciences a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $80.17.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Edwards Lifesciences the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Edwards Lifesciences to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.